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ABSTRACT 
 
Allele-specific  gene  silencing  by  RNA  interference  (RNAi)  is  therapeutically  useful  for  specifically 
suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASP-
RNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is 
vital,  but  is  also  difficult.  Here,  we  show  ASP-RNAi  against  the  Swedish-  and  London-type  amyloid 
precursor protein (APP) variants related to familial Alzheimer’s disease using two reporter alleles encoding 
the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3’-
untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific 
gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which 
were  generated  by  cotransfecting  the  reporter  alleles  and  siRNA  duplexes  into  cultured  human  cells. 
Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona 
fide mutant APP and the production of either amyloid β 40- or 42-peptide in Cos-7 cells expressing both the 
full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles 
may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the 
design and selection of the most suitable of such siRNA duplexes. 
 
KEYWORDS: RNAi, allele-specific gene silencing, amyloid precursor protein, Swedish mutation, London 
mutation, reporter allele 
 
 
INTRODUCTION 
 
RNA interference (RNAi) is a powerful tool for suppressing 
the expression of a gene of interest (Dykxhoorn et al, 2003; 
Meister  and  Tuschl,  2004;  Mello  and  Conte,  2004).  In 
mammals, RNAi can be induced by direct introduction of 
synthetic small interfering RNA (siRNA) duplexes into cells 
or generation of siRNA duplexes using short-hairpin RNA 
expression  vectors  and  its  application  is  expanding  to 
various  fields  of  science;  therapeutic  use  of  RNAi  in 
medical  science  and  pharmacogenesis  is  particularly 
promising (Caplen, 2004; Dykxhoorn et al, 2003; Hannon 
and Rossi, 2004; Karagiannis and El-Osta, 2005; Wood et 
al, 2003).  Allele-specific gene silencing by RNAi (allele-
specific RNAi: ASP-RNAi) is an advanced application of 
RNAi techniques, by which the expression of an allele of 
interest can be inhibited (Victor et al, 2002).  Accordingly, 
ASP-RNAi is thought to  be therapeutically  useful, i.e., it 
can specifically suppress the expression of alleles causing 
disease without inhibiting the expression of corresponding 
wild-type alleles. To realize and control such ASP-RNAi, 
the  following  issues  must  be  addressed:  selection  of 
competent  siRNA  duplexes  that  strongly  induce  ASP-
RNAi; and qualitative and quantitative evaluation of allele-
specific gene silencing. 
 
In  this  article,  we  describe  an  easy  assay  system  for 
assessment  of  ASP-RNAi  with  mutant  and  wild-type 
reporter  alleles  encoding  the  Photinus  and  Renilla 
luciferase  genes.  Using  the  amyloid  precursor  protein  
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(APP) variants (the Swedish- and London-type variants) 
related to familial Alzheimer’s disease (Goate et al, 1991; 
Mullan  et  al,  1992)  as  model  mutant  alleles,  we 
determined  the  effects  of  siRNA  duplexes  against  the 
mutant  APP  on  allele-specific  silencing  as  well  as  off-
target  silencing  against the  wild-type allele. The siRNA 
duplexes having the potential to specifically suppress the 
expression  of  the  mutant  reporter  allele  consistently 
inhibited the expression of the bona fide mutant APP as 
well  as  amyloid  β  40-  and  42-peptides  in  Cos-7  cells 
expressing  both  the  full-length  Swedish-  and  wild-type 
APP alleles.  These observations suggest that the present 
system  could  permit  the  selection  of  siRNA  duplexes 
having the potential to confer ASP-RNAi. 
 
MATERIALS AND METHODS 
 
Preparation of oligonucleotides 
DNA  and  RNA  oligonucleotides  were  obtained  from 
INVITROGEN  and  TAKARA,  respectively.  For 
preparation  of  duplexes,  sense-  and  antisense-stranded 
oligonucleotides (20 µM each) were mixed and annealed 
as described previously (Hohjoh, 2002).  The sequences of 
synthesized oligonucleotides are shown in Tables 1 and 2.  
Non-silencing siRNA duplex (siControl; Qiagen) was used 
as a negative control. 
 
Cell culture 
HeLa,  T98G  and  Cos-7  cells  were  grown  at  37°C  in 
Dulbecco’s modified Eagle’s medium (Wako) supplemented 
with 10% fetal bovine serum (Sigma), 100 U/ml penicillin 
and 100 µg/ml streptomycin (Sigma) in 5% CO2-humidified 
chamber.  T98G  cells  (Registry  No.  IFO50295)  were 
obtained from the Health Science Research Resources Bank. 
 
Construction of reporter and expression plasmids 
In order to construct plasmids carrying reporter alleles, the 
phRL-TK (Promega) and pGL3-TK (Ohnishi et al., 2005) 
plasmids  encoding  the  Renilla  and  Photinus  luciferase 
genes,  respectively,  both  of  which  were  driven  by  the 
same  herpes  simplex  virus  thymidine  kinase  (TK) 
promoter, were digested with Xba I and Not I, and were 
subjected  to  ligation  with  synthetic  oligonucleotide 
duplexes  corresponding  to  the  Swedish-,  London-  and 
wild-type APP alleles (sequences of the oligonucleotides 
used  are  indicated  in  Table  1).    The  resultant  plasmids 
carry allelic APP sequences in the 3’-untranslated regions 
(UTRs)  of  the  luciferase  genes (Figure  1A).  Expression 
plasmids,  pAPP695WT  and  pAPP695SWE  encoding  full-
length cDNAs of the wild- and Swedish-type APP alleles, 
respectively,  were  kindly  provided  by  Dr  Tanahashi 
(Tanahashi and Tabira, 2001). 
 
Transfection and reporter assay 
The day before transfection, cells were trypsinized, diluted 
with fresh medium without antibiotics, and seeded into 24-
well culture  plates  (approximately  0.5  ×  10
5  cells/well).  
Cotransfection of synthetic siRNA duplexes with reporter 
plasmids  was  carried  out  using  Lipofectamine  2000 
transfection  reagent  (Invitrogen)  according  to  the 
manufacturer’s instructions, and to each well, 0.24 µg (40 
nM)  of  siRNA  duplexes,  0.2  µg  of  pGL3-TK-backbone 
plasmid, 0.05 µg of phRL-TK-backbone plasmid and 0.1 
µg of pSV-β-Galactosidase control vector (Promega) were 
applied.  Twenty-four hours after transfection, cell lysate 
was prepared and expression levels  of luciferase and β-
Galactosidase  were  examined  by  the  Dual-Luciferase 
reporter  assay  system  (Promega)  and  Beta-Glo  assay 
system  (Promega),  respectively,  according  to  the 
manufacturer’s instructions.  In the case of transfection of 
siRNA  duplexes  and  expression  plasmids  (pAPP695WT 
and pAPP695SWE) into Cos-7 cells, 0.4 µg of each plasmid 
and 0.24 µg of siRNA duplexes were applied.  Forty-eight 
hours after transfection, culture media was collected and 
cell lysate was prepared. 
 
Western blotting and ELISA 
Culture  media  and  cell  lysate  prepared  from  transfected 
Cos-7 cells were examined by western blotting as described 
previously (Lesne et al., 2003). Equal amounts of proteins 
were  separated  by  SDS-PAGE  and  electrophoretically 
blotted  onto  PVDF  membranes  (Millipore).  Membranes 
were blocked for 1 h in blocking solution (5 % (v/w) fat- 
free  milk  and  0.05  %  (v/v)  Tween-20  in  PBS)  and 
 
 
 
Table 1. Synthetic DNA oligonucleotides 
 
Name  Sequence (5'---------------3') 
ssAPPwt(Sw)  CTAGCATGCAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTCCGACA 
asAPPwt(Sw)  GGCCTGTCGGAATTCTGCATCCATCTTCACTTCAGAGATCTCCTGCATG 
ssAPP(K670N-M671L)  CTAGCATGCAGGAGATCTCTGAAGTGAATCTGGATGCAGAATTCCGACA 
asAPP(K670N-M671L)  GGCCTGTCGGAATTCTGCATCCAGATTCACTTCAGAGATCTCCTGCATG 
ssAPPwt(Lo)  CTAGCATGCTGTCATAGCGACAGTGATCGTCATCACCTTGGTGATGCTGA 
asAPPwt(Lo)  GGCCTCAGCATCACCAAGGTGATGACGATCACTGTCGCTATGACAGCATG 
ssAPP(V717I )  CTAGCATGCTGTCATAGCGACAGTGATCATCATCACCTTGGTGATGCTGA 
asAPP(V717I )  GGCCTCAGCATCACCAAGGTGATGATGATCACTGTCGCTATGACAGCATG 
ssAPP(V717F )  CTAGCATGCTGTCATAGCGACAGTGATCTTCATCACCTTGGTGATGCTGA 
asAPP(V717F )  GGCCTCAGCATCACCAAGGTGATGAAGATCACTGTCGCTATGACAGCATG 
ssAPP(V717G)  CTAGCATGCTGTCATAGCGACAGTGATCGGCATCACCTTGGTGATGCTGA 
asAPP(V717G )  GGCCTCAGCATCACCAAGGTGATGCCGATCACTGTCGCTATGACAGCATG  
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Table 2. Synthetic siRNAs used in this study. Sense- and 
antisense-stranded siRNA elements are indicated by ‘-ss’ and ‘-
as’, respectively. 
 
 
siRNAs against the Swedish APP mutant 
Name  Sequence (5'---------------3') 
si(T7/C8)-ss  AGUGAAUCUGGAUGCAGAAUUU 
si(T7/C8)-as  AUUCUGCAUCCAGAUUCACUUU 
si(T8/C9)-ss  AAGUGAAUCUGGAUGCAGAAUU 
si(T8/C9)-as  UUCUGCAUCCAGAUUCACUUUU 
si(T9/C10)-ss  GAAGUGAAUCUGGAUGCAGAUU 
si(T9/C10)-as  UCUGCAUCCAGAUUCACUUCUU 
si(T10/C11)-ss  UGAAGUGAAUCUGGAUGCAGUU 
si(T10/C11)-as  CUGCAUCCAGAUUCACUUCAUU 
si(T11/C12)-ss  CUGAAGUGAAUCUGGAUGCAUU 
si(T11/C12)-as  UGCAUCCAGAUUCACUUCAGUU 
si(T12/C13)-ss  UCUGAAGUGAAUCUGGAUGCUU 
si(T12/C13)-as  GCAUCCAGAUUCACUUCAGAUU 
 
siRNAs against the London APP mutants 
Name  Sequence (5'---------------3') 
si(A8)-ss  AGUGAUCAUCAUCACCUUGUU 
si(A8)-as  CAAGGUGAUGAUGAUCACUUU 
si(A9)-ss  CAGUGAUCAUCAUCACCUUUU 
si(A9)-as  AAGGUGAUGAUGAUCACUGUU 
si(A10)-ss  ACAGUGAUCAUCAUCACCUUU 
si(A10)-as  AGGUGAUGAUGAUCACUGUUU 
si(A11)-ss  GACAGUGAUCAUCAUCACCUU 
si(A11)-as  GGUGAUGAUGAUCACUGUCUU 
si(A12)-ss  CGACAGUGAUCAUCAUCACUU 
si(A12)-as  GUGAUGAUGAUCACUGUCGUU 
si(T8)-ss  AGUGAUCUUCAUCACCUUGUU 
si(T8)-as  CAAGGUGAUGAAGAUCACUUU 
si(T9)-ss  CAGUGAUCUUCAUCACCUUUU 
si(T9)-as  AAGGUGAUGAAGAUCACUGUU 
si(T10)-ss  ACAGUGAUCUUCAUCACCUUU 
si(T10)-as  AGGUGAUGAAGAUCACUGUUU 
si(T11)-ss  GACAGUGAUCUUCAUCACCUU 
si(T11)-as  GGUGAUGAAGAUCACUGUCUU 
si(T12)-ss  CGACAGUGAUCUUCAUCACUU 
si(T12)-as  GUGAUGAAGAUCACUGUCGUU 
si(G8)-ss  GUGAUCGGCAUCACCUUGGUU 
si(G8)-as  CCAAGGUGAUGCCGAUCACUU 
si(G9)-ss  AGUGAUCGGCAUCACCUUGUU 
si(G9)-as  CAAGGUGAUGCCGAUCACUUU 
si(G10)-ss  CAGUGAUCGGCAUCACCUUUU 
si(G10)-as  AAGGUGAUGCCGAUCACUGUU 
si(G11)-ss  ACAGUGAUCGGCAUCACCUUU 
si(G11)-as  AGGUGAUGCCGAUCACUGUUU 
si(G12)-ss  GACAGUGAUCGGCAUCACCUU 
si(G12)-as  GGUGAUGCCGAUCACUGUCUU 
were incubated with anti-APP antibody 22C11 (Chemicon) or 
anti-α-tubulin antibody DM1A (Sigma) followed by washing 
in PBS  and further  incubation  with  horseradish  peroxidase-
conjugated donkey anti-mouse IgG (Jackson ImmunoResearch 
Laboratories).  Antigen-antibody  complexes  were  visualized 
using ECL chemiluminescent reagent (Amersham).  Levels of 
Aβ40 and Aβ42 production in culture media were examined by 
human/rat β amyloid 40 and 42 ELISA kits (Wako) according 
to the manufacturer’s instructions. 
 
RT-PCR 
Total  RNA  extraction,  including  treatment  with  DNase  I 
(Ambion)  twice  followed  by  reverse  transcription,  were 
carried out as described previously (Sago et al., 2004).  The 
resultant  cDNAs  were  examined  by  real-time  (RT)-PCR 
using  the  ABI  PRISM  7300  sequence  detection  system 
(Applied  Biosystems)  with  a  SYBER  green  PCR  master 
mix (Applied Biosystems) according to the manufacturer’s 
instructions.  PCR primers used were as follows: 
 
For detection of the Renilla luciferase transcript: 
 
renilla-F; 5’-GTTCTTTTCCAACGCTATTG-3’ 
renilla-R; 5’-GAAGCTCTTGATGTACTTAC-3’ 
 
For detection of the Photinus luciferase transcript: 
 
photinus-F; 5’-TTTGATATGTGGATTTCGAG-3’ 
photinus-R; 5’-ATCGTATTTGTCAATCAGAG-3’ 
 
RESULTS 
 
Assessment of siRNAs in heterozygous model system 
In this study, the Swedish- and London-type mutants of the 
APP  gene,  which  are  involved  in  familial  Alzheimer’s 
disease, were used as model mutant alleles.  The Swedish- 
and  London-type  APP  mutants  carry  double  and  single 
nucleotide substitutions, respectively, which are followed by 
amino  acid  substitutions  (K670N-M671L  in  the  Swedish 
APP; V717I, V717F or V717G in the London APP) (Goate 
et al, 1991; Mullan et al, 1992). The resultant amino acid 
sequences  in  the  Swedish  and  London-type  APPs  are 
preferably  digested  by  β-  and  γ-secretase,  respectively, 
resulting  in  accumulation  of  Aβ40  and  Aβ42  peptides, 
which are the key factors of Alzheimer’s disease (Cai et al, 
1993; Citron et al, 1992; Mattson, 2004; Suzuki et al, 1994). 
 
Mutant and wild-type reporter alleles were constructed as 
described in Materials and Methods.  The resultant reporter 
alleles  (Figure  1A),  synthetic  siRNA  duplex  against  the 
mutant allele and the β-galactosidase gene (control) were 
cotransfected into human cells.  Note that the transfected 
cells are artificially heterozygous with the mutant and wild-
type APP reporter alleles; thus, the effects of test siRNA 
duplexes on suppression of both the mutant and wild-type 
alleles can be simultaneously examined. 
 
ASP-RNAi against the Swedish-type APP allele 
When  the  Renilla  and  Photinus  luciferase  genes  were 
regarded  as  the  Swedish  and  wild-type  reporter  alleles, 
respectively,  the  effects  of  the  si(T7/C8)  -  si(T12/C13) 
duplexes  against  the  Swedish  mutant  on  allele-specific 
gene silencing  were examined  in HeLa  cells.  The results   
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Figure 1. Assessment of ASP-RNAi with reporter alleles.  (A) 
Schematic drawing of reporter alleles.  Reporter alleles were 
constructed based on the Photinus and Renilla luciferase reporter 
genes driven by the same TK promoter, and allelic sequences of 
wild-type and mutant (synthetic oligonucleotides) were inserted 
into the 3’-UTRs of the reporter genes, i.e., the reporter alleles 
encode luciferase reporter genes carrying artificially inserted 
allele sequences of interest.  Assessment of siRNA duplexes on 
the induction of ASP-RNAi against the Swedish APP mutant (B) 
and against the London APP mutants (C-E) was carried out.  
Synthetic siRNA duplexes against the mutants indicated were 
cotransfected with the mutant and wild-type reporter alleles and 
the β-galactosidase gene (control) into HeLa cells.  The Photinus 
and Renilla luciferase genes carry the mutant and wild-type 
allelic sequences, respectively.  Twenty-four hours after 
transfection, dual-luciferase and β-galactosidase assays were 
carried out.  The levels of either Photinus (blue boxes) or Renilla 
(pink boxes) luciferase activity was normalized against the levels 
of β-galactosidase activity, and the ratios of mutant and wild-
type luciferase activities in the presence of siRNA duplexes were 
normalized against the control ratio obtained in the presence of 
the siControl duplex (siCont).  Data are averages of at least three 
independent determinations.  Error bars represent standard 
deviations. 
 
 
 
are shown in Figure 1B.  The siRNA duplexes, except for 
the  si(T12/C13)  duplex,  appeared  to  induce  inhibition  of 
mutant (Photinus) allele expression, while little or moderate 
inhibition of wild-type (Renilla) allele expression was seen, 
suggesting  that  the  siRNA  duplexes  were  able  to 
discriminate the mutant reporter allele from the wild-type 
reporter allele.  The si(T12/C13) duplex appeared to yield 
little or no RNAi activity.  Considering the influence of the 
siRNA duplexes on the expression of the wild-type allele, 
the si(T8/C9) duplex appears to be the most suitable siRNA 
duplex conferring ASP-RNAi against the mutant allele.  As 
for  the  si(T9/C10)  and  si(T11/12)  duplexes  inducing 
moderate levels of inhibition of wild-type allele expression, 
further analyses were carried out (Figure 4).  Similar results 
were  also  obtained  when  the  luciferase  genes  were 
exchanged  between  the  mutant  and  wild-type  reporter 
alleles,  i.e.,  the  Photinus  and  Renilla  luciferase  genes 
carried  the  wild-type  and  Swedish  allele  sequences, 
respectively (data not shown). In addition, when T98G cells, 
a human glioblastoma cell line, and Cos-7 cells were used 
instead of HeLa cells, results similar to those obtained in 
HeLa cells were observed (data not shown). 
 
ASP-RNAi against London-type APP alleles 
Because the London-type mutant possesses three types of 
single nucleotide change involved in amino acid substitution 
at position 717 (V717I, V717F and V717G), three mutant 
reporter alleles and corresponding wild-type reporter allele 
were  constructed,  and  the  effects  of  synthetic  siRNA 
duplexes against the London-type mutants on suppression of 
the expression of either the target mutant allele or wild-type 
allele were examined under the present system. As shown in 
Figure 1C-E, various levels of gene silencing were observed 
and some of the siRNA duplexes, si(T9) and si(T12) (Figure 
1D), appeared to discriminate the mutant alleles from the 
wild-type  allele  to  some  degree,  resulting  in  ASP-RNAi; 
however, the other siRNA duplexes examined yielded less 
significant ASP-RNAi. Compared with the results for ASP-
RNAi against the Swedish allele (Figure 1B), the induction 
and  activation  of  ASP-RNAi  against  the  London  alleles 
appeared to be inferior to those against the Swedish mutant. 
 
Western blot analyses of wild-type and Swedish APP in 
ASP-RNAi 
We  further  investigated  ASP-RNAi  of  siAPP  duplexes 
against the Swedish mutant with full-length cDNAs of the 
Swedish and wild-type APP alleles, which were transiently 
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expressed  in  Cos-7  cells.  The  pAPP695SWE  and/or 
pAPP695WT  expression  plasmids  encoding  full-length 
cDNAs  of  the  Swedish  and  wild-type  APP  alleles, 
respectively, and siRNA duplexes targeting the Swedish 
mutant were cotransfected into Cos-7 cells, and expression 
of wild-type APP (APPWT) and Swedish APP (APPSWE) 
was examined by Western blotting. As shown in Figure 2, 
under  homo(or  hemi)zygous-like  conditions,  in  which 
either  APPWT  or  APPSWE  was  expressed,  the  signal 
intensity of sAPPSWE (secreted APP) and cAPPSWE (celluar 
APP)  was  apparently  decreased  in  the  presence  of  the 
si(T8/C9),  si(T9/C10)  and  si(T11/C12)  duplexes.  In 
contrast,  signals  for  either  sAPPWT  or  cAPPWT  were 
detected  in  the  presence  of  any  of  the  siRNA  duplexes 
examined,  which  is  consistent  with  the  data  for  the 
reporter  alleles  described  above.    When  APPSWE  and 
APPWT were both expressed in the cells (heterozygous-like 
conditions), signals for APP were seen in the presence of 
any of  the siRNA duplexes. Based  on the results  under 
homozygous-like  conditions,  the  signals  for  APP  in  the 
presence  of  the  si(T8/C9),  si(T9/C10)  and  si(T11/C12) 
duplexes were most likely derived from APPWT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Expression of APPWT and APPSWE polypeptides 
under ASP-RNAi.  Either the pAPP695WT (A) and 
pAPP695SWE (B) expression plasmids or the plasmids (C) 
together with the indicated siRNA duplexes against the 
Swedish mutant were introduced into Cos-7 cells, and 
expressed APP polypeptides in culture media (secreted APP: 
sAPP) and in cells (cellar APP: cAPP) were examined by 
Western blotting.  Lane 1 (control) shows no transfected Cos-7 
cells, in which endogenous APP is detectable.  Lanes 2-9 are 
cells transfected with expression plasmid(s), and lanes 3-9 are 
cotransfected cells with the indicated siRNA duplexes.  
Expression of α-tubulin (control) is also shown. 
The  utility  of  ASP-RNAi  using  the  siRNA  duplexes 
assessed here in medical treatment can be demonstrated by 
confirming a significant decrease in Aβ peptides, which 
are a key factor in the development of Alzheimer’s disease 
under  heterozygous  conditions  expressing  both  APPSWE 
and APPWT.  We thus determined the production levels of 
Aβ40 and Aβ42 peptides by means of ELISA.  As shown 
in  Figure  3,  significant  decreases  in  the  production  of 
either Aβ40 or Aβ42 peptide by RNAi (Figure 3A-C) and 
ASP-RNAi  (Figure  3D-F)  with  the  evaluated  siRNA 
duplexes,  particularly  si(T8/C9),  si(T9/C10)  and 
si(T11/C12),  was  confirmed  under  homozygous  and 
heterozygous  conditions,  respectively.  Therefore,  these 
results  suggest  the  potential  utility  of  such  siRNA 
duplexes as therapeutic agents. 
 
DISCUSSION 
 
While ASP-RNAi is believed to be a useful technique, to 
realize and  control  ASP-RNAi, it is  vital  to  design  and 
select competent siRNA duplexes conferring ASP-RNAi; 
however, this  is rather  difficult  without a  procedure  for 
assessing such siRNA  duplexes. The system we  present 
here could allow assessment, if designed siRNA duplexes 
have the potential for specifically inhibiting the expression 
of  target  alleles  without  suppressing  the  expression  of 
other  alleles.  From  a  series  of  experiments  with  the 
Swedish- and London-type APP variants as model mutant 
alleles,  we  were  able  to  determine  potential  siRNA 
duplexes for inducing ASP-RNAi. With regard to siRNA 
duplexes  targeting  the  Swedish  mutant,  we  further 
demonstrated  that  the  si(T8/C9),  si(T9/C10)  and 
si(T11/C12)  siRNA  duplexes  were  able  to  significantly 
decrease the production of either Aβ40 or Aβ42 peptide in 
Cos-7 cells expressing both the full-length Swedish- and 
wild-type  APP  alleles.  Accordingly,  such  competent 
siRNA  duplexes  conferring  ASP-RNAi  against  mutant 
alleles likely hold utility as therapeutic agents. 
 
In contrast to the Swedish mutant, there were difficulties in 
suppressing  the  London-type  mutants  carrying  single 
nucleotide substitutions from the wild-type allele by ASP-
RNAi. The difference between ASP-RNAi activities against 
the  Swedish-  and  London-type  mutants  may  have  been 
caused by the number of base substitutions: the former and 
latter  mutants  carry  double  and  single  base  substitutions, 
respectively. Another important point to note in the results 
for  the  London-type  mutant  is  that  different  substitutions 
showed different ASP-RNAi activities, suggesting that the 
type  of  base  change  between  the  mutant  and  wild-type 
alleles  could  influence  ASP-RNAi.    With  regard  to  the 
V717I  (Figure  1C)  and  V717G  (Figure  1E)  mutants,  a 
possible wobble base pair between siRNA and the wild-type 
mRNA (Du et al,  2005) and high GC content  of siRNA 
used(Ui-Tei  et  al,  2004),  respectively,  might  have 
negatively  influenced  the  induction  of  ASP-RNAi;  these 
possibilities require further examination in the future.   
 
To further progress ASP-RNAi, it is necessary to design 
competent  siRNA  duplexes  conferring  strong  allele-
specific gene silencing.  Chemical modifications (Chiu and 
Rana,  2003;  Hall  et  al,  2004)  and  structural  devices  in 
siRNAs  are  considered  to  be  applicable  for  improving 
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ASP-RNAi,  and  assessment  of  such  siRNAs  is  feasible 
using  the  system  we  presented  here.    Altogether,  it  is 
suggested that the present assay system may contribute to 
the  design  and  selection  of  the  most  suitable  of siRNA 
duplexes conferring ASP-RNAi.   
 
Finally, we add data indicating the possible inhibition of 
wild-type allele translation by the present siRNA duplexes.  
Because si(T9/C10) and si(T11/C12) exhibited moderate 
levels of inhibition of the expression of wild-type reporter 
allele (Figure 1B), we further investigated RNA levels of 
the wild-type allele by RT (real-time)-PCR.  As shown in 
Figure 4, the levels of RNA expression of the wild-type 
allele in the presence of si(T9/C10) were similar to those 
in  the  presence  of  siControl,  suggesting  the  possible 
inhibition  of  translation  of  the  wild-type  allele  by  the 
si(T9/C10) duplex.  This may be due to a microRNA-like 
effect (Poy et al, 2004; Tang, 2005), and further study into 
this  possibility  remains  necessary.    With  regard  to  the 
si(T11/C12) duplex, because a decrease trend in the levels 
of wild-type allele transcript was seen, it is possible that 
off-target gene silencing (Jackson et al, 2003) of the wild-
type  allele  may  occur  in  the  presence  of  the  duplex.  
Consequently,  it  is  conceivable  that  the  present  system 
could  further  contribute  to  studies  into  off-target  gene 
silencing and the function of microRNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Production of Aβ40 and Aβ42 peptides under ASP-RNAi.  The pAPP695SWE (A-C) plasmid and both the pAPP695SWE and 
pAPP695WT (D-F) plasmids together with the indicated siRNA duplexes against the Swedish mutant were cotransfected into Cos-7 cells, and 
expressed sAPP polypeptide and Aβ40 and Aβ42 peptides in culture media were examined by western blotting (A, D) and ELISA (B, C, E, F), 
respectively.  “Vector” indicates cells transfected with only plasmid(s).  Endogenous and exogenous (expressed) sAPPs are indicated by asterisks 
and arrow heads, respectively.  ELISA data are averages of three independent determinations.  Error bars represent standard deviations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Possible translation inhibition and off-target silencing of wild-type reporter allele by siAPP duplexes. The si(T9/C10) or 
si(T11/C12) duplexes against the Swedish mutant allele together with either wild or mutant reporter allele plasmid carrying Photinus 
luciferase and the phRL-TK plasmid encoding Renilla luciferase (control) were introduced into HeLa cells. Twenty-four hours after 
transfection, dual-luciferase assay and isolation of total RNA were carried out. Off-target (to wild-type reporter allele) (A) and on-
target (RNAi; to mutant reporter allele) (C) gene silencing were assessed based on luciferase activities.  Ratios of normalized target 
(Photinus) luciferase activity to control (Renilla) luciferase activity are indicated: the ratios of luciferase activity determined in the 
presence of the si(T9/C10) or si(T11/C12) duplexes were normalized against the ratios obtained in the presence of the siControl 
duplex (siCont).  Isolated RNAs in (B) and (D) corresponding to (A) and (C), respectively, were subjected to reverse transcription to 
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synthesize first-stranded cDNAs.  The resultant cDNAs were examined by real-time PCR with specific primers for Photinus and 
Renilla luciferase.  RNA expression levels for Photinus luciferase are normalized against those of Renilla luciferase, and the ratios of 
Photinus luciferase RNA expression levels in the presence of the si(T9/C10) or si(T11/C12) duplexes are normalized against the 
ratios obtained in the presence of the siControl duplex.  Data are averages of at least three independent determinations.  Error bars 
represent standard deviations. 
 
 
CONCLUSIONS 
 
The  present  assay  system  with  wild-type-  and  mutant-
reporter  alleles  could  permit  assessment  of  siRNA 
duplexes having the potential for specifically inhibiting the 
expression  of  the  mutant  allele  without  inhibiting  the 
expression of the wild-type allele, and thus contribute to 
the design and selection of siRNA duplexes suitable for 
allele-specific gene silencing. 
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